Direct to consumer advertising versus disease awareness advertising: Consumer perspectives from down under

Journal of Public Affairs

Volumn 11, Issue 1, 2011, Pages 60-69

  Hall, Danika Valerie ^a   Jones, Sandra Carol ^a   Hoek, Janet ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951603955     PISSN: 14723891     EISSN: 14791854     Source Type: Journal    
DOI: 10.1002/pa.379     Document Type: Article

References (68)

1. Advertising Standards Authority New Zealand. 2008. Advertising standards complaints board. [August 2008].
2. Advertising Standards Authority New Zealand. 2009. Advertising standards complaints board. [August 2008].
3. Angelmar R, Angelmar S, Kane L. 2007. Building strong condition brands. Journal of Medical Marketing 7: 341-351. DOI: 10.1057/palgrave.jmm.5050101.
4. ANZTPA. 2005. Australia New Zealand Therapeutic Products Draft Advertising Code. [June 2007].
5. Australian Government Department of Health and Ageing. 2007. Therapeutic Goods Advertising Code. [May 2007].
6. Auton F. 2004. The advertising of pharmaceuticals direct to consumers: a critical review of the literature and debate. International Journal of Advertising 23: 5-52.
7. Auton F. 2007. The patient as consumer: the advertising of pharmaceuticals to consumers should be allowed and encouraged. Economic Affairs 64-72. DOI: 10.1111/j.1468-0270.2007.00732.x.
8. Barry P. 2000. Stories in 2000. In Australian Broadcasting Corporation (Ed.) Media Watch. Australia. [November 2009].
9. Basara LR. 1996. The impact of a direct-to-consumer prescription medication advertising campaign on new prescription volume. Drug Information Journal 30: 715-729.
10. Bonaccorso SN, Sturchio JL. 2002. Education and debate: direct to consumer advertising is medicalising normal human experience. British Medical Journal 324: 910-911. DOI: 10.1136/bmj.324.7342.910.
11. Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM. 2004. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. Journal of Health Communication 9: 491-497. DOI: 10.1080/10810730490523115.
12. Calfee JE. 2002. Public policy issues in direct-to-consumer advertising of prescription drugs. Journal of Public Policy & Marketing 21(2): 174-193. DOI: 10.1509/jppm.21.2.174.17580.
13. Coney S. 2002. Direct-to-consumer advertising of prescription pharmaceuticals: a consumer perspective from New Zealand. Journal of Public Policy & Marketing 21(2): 213-223. DOI: 10.1509/jppm.21.2.213.17592.
14. DeLorme DE, Huh J, Reid LN. 2007. "Others are influenced, but not me": older adults' perceptions of DTC prescription drug advertising effects. Journal of Aging Studies 21: 135-151. DOI: 10.1016/j.jaging.2006.06.001.
15. Deshpande A, Menon A, Perri M, Zinkhan G. 2004. Direct-to-consumer advertising and its utility in health care decision making: a consumer perspective. Journal of Health Communication 9: 499-513. DOI: 10.1080/10810730490523197.
16. Donohue J. 2006. A history of drug advertising: the evolving roles of consumers and consumer protection. The Millbank Quarterly 84(4): 659-699. DOI: 10.1111/j.1468-0009.2006.00464.
17. Friedman M, Gould J. 2007a. Consumer attitudes and behaviours associated with direct-to-consumer prescription drug marketing. Journal of Consumer Marketing 24(2): 100-109. DOI: 10.1108/07363760710737102.
18. Friedman M, Gould J. 2007b. Physicians' attitudes toward direct-to-consumer prescription drug marketing. Journal of Medical Marketing 7(1): 33-44. DOI: 10.1057/palgrave.jmm.5050063.
19. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. 2007. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Annals of Family Medicine 5(1): 6-13. DOI: 10.1370/afm.611.
20. Gardner DM, Mintzes B, Ostry A. 2003. Direct-to-consumer prescription drug advertising in Canada: permission by default? Canadian Medical Association Journal 169(5): 425-427.
21. Glatter J. 2004. Promotion, information and advertising: why increasingly blurred boundaries do not benefit the public. Journal of Generic Medicines 1(2): 128-136. DOI: 10.1057/palgrave.jgm.494004.
22. Hall DV. 2008. High levels of confusion for cholesterol awareness campaigns. Medical Journal of Australia 189(6): 326-328.
23. Hall DV, Jones SC. 2007. Branding of prescription medicines to Australian consumers. Australasian Marketing Journal 15(2): 97-107.
24. Hall DV, Jones SC, Iverson DC. 2009. A content analysis of disease awareness advertisements in popular Australian women's magazines. Medical Journal of Australia 191(11/12): 625-629.
25. Handlin A, Mosca JB, Forgione DA, Pitta D. 2003. DTC pharmaceutical advertising: the debate's not over. Journal of Consumer Marketing 20(3): 227-237. DOI: 10.1108/07363760310472254.
26. Hastings G, Stead M, Webb J. 2004. Fear appeals in social marketing: strategic and ethical reasons for concern. Psychology and Marketing 21(11): 961-986. DOI: 10.1002/mar.20043.
27. Hoek J, Gendall P. 2002. Direct-to-consumer advertising down under: an alternative perspective and regulatory framework. Journal of Public Policy & Marketing 21(2): 202-212. 10.1509/jppm.21.2.202. 17586.
28. Hoek J, Gendall P. 2004. Regulation of prescription medicine advertising in the United States and New Zealand: A consumer perspective. In WAPOR Conference. Phoenix, Arizona.
29. Hoek J, Gendall P, Calfee J. 2004. Direct-to-consumer advertising of prescription medicines in the United States and New Zealand: an analysis of regulatory approaches and consumer responses. International Journal of Advertising 23(2): 197-228.
30. IMS Health. 2008. Total US promotional spend by type, 2007. [June 2009].
31. Jacobson MF. 2005. Lifting the veil of secrecy from industry funding of nonprofit health organisations. International Journal of Occupational and Environmental Health 11: 349-355.
32. Jones SC, Mullan J. 2006. Older adults' perceptions and understanding of DTCA. Journal of Consumer Marketing 23(1): 6-14. DOI: 10.1108/0736760610641118.
33. Kaphingst KA, DeJong W. 2004. The educational potential of direct-to-consumer prescription drug advertising. Health Affairs 23(4): 143-150. DOI: 10.1377/hlthaff.23.4.143.
34. Kaphingst KA, Dejong W, Rudd RE, Daltroy LH. 2004. A content analysis of direct-to-consumer television prescription drug advertisements. Journal of Health Communication 9(6): 515-528. DOI: 10.1080/10810730490882586.
35. Kaphingst KA, Rudd RE, DeJong W, Daltroy LH. 2005. Comprehension of information in three direct-to-consumer television prescription drug advertisements among adults with limited literacy. Journal of Health Communication: International Perspectives 10(7): 609-619. DOI: 10.1080/10810730500267647.
36. Macias W, Pashupati K, Lewis LS. 2007. A wonderful life or diarrhea and dry mouth? Policy issues of direct-to-consumer drug advertising on television. Health Communication 22(3): 241-252.
37. Mackenzie FJ, Jordens FC, Ankeny RA, McPhee J, Kerridge IH. 2007. Direct-to-consumer advertising under the radar: the need for realistic drugs policy in Australia. Internal Medicine Journal 37: 224-228. DOI: 10.1111/j.1445-5994.2006.01298.
38. Mandese J. 2005. TV execs welcome drug ads with open arms. [26 June 2009].
39. Medicines Australia. 2009. Code of Conduct Edition 16. [November 2009].
40. Mehta A, Purvis SC. 2003. Consumer response to print prescription drug advertising. Journal of Advertising Research 43: 194-206.
41. Miller KE, Waller DS. 2004. Attitudes towards DTC advertising in Australia: an exploratory study. International Journal of Advertising 23: 389-405.
42. Ministry of Health. 2000. Direct-to-consumer advertising of prescription medicines in New Zealand. A Discussion Paper. Wellington: Ministry of Health.
43. Ministry of Health. 2006a. Direct-to-consumer advertising of prescription medicines in New Zealand. Consultation Document. Wellington: Ministry of Health.
44. Ministry of Health. 2006b. Direct-to-consumer advertising of prescription medicines in New Zealand. Summary of Submissions. Wellington: Ministry of Health.
45. Mintzes B. 2002. Direct-to-consumer prescription drug advertising: is there evidence of health benefits? Essential Drugs Monitor 31: 16-19.
46. Mintzes B. 2006. Disease mongering in drug promotion: do governments have a regulatory role? Public Library of Science: Medicine 4(3): 1-5. DOI: 10.1371/journal.pmed.0030198.
47. Moynihan R, Bay B. 2007. Consumers fight to halt move towards direct to consumer advertising in Europe. British Medical Journal 334(1025): DOI: 10.1136/bmj.39212.645486.
48. Moynihan R, Henry D. 2006. The fight against disease mongering: generating knowledge for action. Public Library of Science: Medicine 3(4): 1-4. DOI: 10.1371/journal.pmed.0030191.
49. Murray E, Lo B, Pollack L, Donelan K, Lee K. 2003. Direct-to-consumer advertising: physicians' views of its effects on quality of care and the doctor-patient relationship. Journal of the American Board of Family Practice 16: 513-524. DOI: 10.3122/jabfm.16.6.5.
50. Murray E, Lo B, Pollack L, Donelan K, Lee K. 2004. Direct-to-consumer advertising: public perceptions of its effects on health behaviours, health care, and the doctor-patient relationship. Journal of the American Board of Family Practice 17(1): 6-18. DOI: 10.3122/jabfm.17.1.
51. Nielsen Media Research AdEx. 2006. Special Report, 2006 Top 50 Advertisers. In B&T Weekly. Sydney.
52. Royne MB, Myers SD. 2008. Recognizing consumer issues in DTC pharmaceutical advertising. The Journal of Consumer Affairs 42(1): 60-80. DOI: 10.1111/j.1745-6606.2007.00094.
53. Stotka JL, Rotelli MD, Dowsett SA, Elsner MW, Holdsworth SM, Pitts PJ, McAvoy DR. 2007. A new model for communicating risk information in direct-to-consumer print advertisements. Drug Information Journal 41(1): 111-127.
54. t'Jong GW, Stricker BHC, Sturkenboom MCJM. 2004. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. British Medical Journal 328: 931. DOI: 10.1136/bmj.38007.711481.
55. The Nielsen Company. 2010. Insights to drive pharma-health brand and digital strategies: Solutions for pharma health marketers 2010. [September 2010].
56. Toop L, Mangin D. 2006. The impact of advertising prescription medicines directly to consumers in New Zealand: lessons for Australia. Australian Prescriber 29(2): 30-332.
57. Toop L, Mangin D. 2007. Industry funded patient information and the slippery slope to New Zealand. British Medical Journal 355: 694-695. DOI: 10.1136/bmj.39346.525764.
58. Toop L, Richards D, Dowell T, Tilyard M, Fraser T, Arroll B. 2003. DTCA in New Zealand: Report to Minister of Health supporting the ban on DTCA. New Zealand Departments of General Practice Christchurch, Dunedin, Wellington and Auckland Schools of Medicine.
59. US GAO. 2006. Prescription drugs: improvements needed in FDA's oversight of direct-to-consumer advertising. In GAO Report Number GAO-07-54: US General Accounting Office.
60. USA Today, Kaiser Family Foundation, Harvard School of Public Health. 2008. The public on prescription drugs and pharmaceutical companies. [April 2008].
61. Usher W, Skinner J. 2009. Persuasion and types of enticements offered by pharmaceutical companies to Gold Coast general practitioners in an attempt to encourage a health website recommendation. Health & Social Care in the Community 18(1): 100-105. DOI: 10.1111/j.1365-2524.2009.00879.x.
62. Vatjanapukka V, Waryszak R. 2004. Relationship between consumer knowledge, prescription drug advertising exposure and attitudes towards direct-to-consumer prescription drug advertising. International Journal of Medical Marketing 4(4): 350-360. DOI: 10.1057/palgrave.jmm.50401.
63. Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, Feibelmann S. 2004. Physicians report on patient encounters involving direct-to-consumer advertising. Health Affairs W4: 219-233. DOI: 10.1377/hlthaff.w4.219.
64. White RW, Horvitz E. 2009. Cyberchondria: Studies of the escalation of medical concerns in web search. ACM Transactions on Information Systems 27(4): 101137-101145/1629096-1629101.
65. Wielondek M. 2005. Can direct-to-consumer advertising help in re-inventing the image of the pharmaceutical industry instead of eroding its credibility? Journal of Medical Marketing 5(3): 264-273. DOI: 10.1057/palgrave.jmm.5040239.
66. Wijesinghe PR, Norris P. 2008. Increased advertising of medicines on New Zealand television since 2001. New Zealand Medical Journal 121(1271): 121-122.
67. Woloshin S, Schwartz LM. 2006. Giving legs to restless legs: a case study of how the media helps make people sick. Public Library of Science: Medicine 3(4): 1-4. DOI: 10.1371/journal.pmed.0030170.
68. Woloshin S, Schwartz LM, Tremmel J, Welch HG. 2001. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? The Lancet 358(9288): 1141-1146. DOI: 10.1016/S0140-6736(01)06254.